ACQUISITION OF IVERIC BIO

from the beginning

ACQUISITION OF IVERIC BIO

@

@

• ACQUISITION OF IVERIC BIO

@

@

• AGENDA

• TRANSACTION SUMMARY

• IVERIC BIO OVERVIEW

• STRATEGIC RATIONALE OF ACQUISITION

• AVACINCAPTAD PEGOL (ACP) OVERVIEW

• GEOGRAPHIC ATROPHY (GA) OVERVIEW

• SELECTED CLINICAL PIPELINE ASSETS TARGETING GEOGRAPHIC ATROPHY (GA)

• PIVOTAL TRIALS (GATHER1 AND GATHER2): OVERVIEW

• PIVOTAL TRIALS (GATHER1 AND GATHER2): EFFECT ON GA AREA

• PIVOTAL TRIALS (GATHER1 AND GATHER2): EFFECT ON VISION LOSS

• PIVOTAL TRIALS (GATHER1 AND GATHER2): SAFETY

• REVENUE CONTRIBUTION OF ACP (ILLUSTRATIVE)

• ESTABLISHING FOUNDATIONAL OPHTHALMOLOGY CAPABILITIES

• FINANCIAL CONSIDERATIONS

APPENDIX

• MECHANISM OF ACTION

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9

• Questions 10

• Questions 11

• Questions 12

• Questions 13